Cancer reports (Hoboken, N.J.) · 2025
Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arima Junya, Yoshino Hirofumi, Tatarano Shuichi, Mitsuke Akihiko, Osako Yoichi, Sakaguchi Takashi, Matsushita Ryosuke, Inoguchi Satoru, Yamada Yasutoshi, Enokida Hideki
Аннотация
BACKGROUND: Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second-line treatment for urothelial cancer (UC) extends prognosis by only 3 months.
AIMS: This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.
METHODS AND RESULTS: The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; p = 0.004) and overall survival (OS; p = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, p = 0.0008) and OS (hazard ratio: 0.105, p = 0.0056).
CONCLUSION: These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.
AIMS: This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.
METHODS AND RESULTS: The study included 44 patients who had recurrence or progression after first-line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression-free survival (PFS; p = 0.004) and overall survival (OS; p = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, p = 0.0008) and OS (hazard ratio: 0.105, p = 0.0056).
CONCLUSION: These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.
Предметные рубрики MeSH
HumansMaleRetrospective StudiesFemaleAntibodies, Monoclonal, HumanizedAgedMiddle AgedPrognosisAntineoplastic Combined Chemotherapy ProtocolsClostridium butyricumCarcinoma, Transitional CellProbioticsAged, 80 and overProgression-Free SurvivalImmune Checkpoint InhibitorsUrologic NeoplasmsNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsAdultCarboplatinCisplatin